Which has preferable valuation & earnings, ANL or ZYME?

Adlai Nortye has higher earnings, but lower revenue than Zymeworks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 81.60 -$35.53M N/A N/A Zymeworks $105.96M 15.83 -$81.13M -$1.37 N/A

Is ANL or ZYME more profitable?

Adlai Nortye has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Adlai Nortye's return on equity of 0.00% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Zymeworks -126.92% -37.97% -25.31%

Which has better valuation and earnings, AAPG or ANL?

Adlai Nortye has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.45 -$177.71M N/A N/A Adlai Nortye $5M 81.60 -$35.53M N/A N/A

Is AAPG or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Adlai Nortye N/A N/A N/A

Which has preferable earnings & valuation, NBTX or ANL?

Nanobiotix has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 46.49 -$27.11M N/A N/A Adlai Nortye $5M 81.60 -$35.53M N/A N/A

Is NBTX or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Adlai Nortye N/A N/A N/A

Which has better valuation and earnings, ANL or RXRX?

Adlai Nortye has higher earnings, but lower revenue than Recursion Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 81.60 -$35.53M N/A N/A Recursion Pharmaceuticals $74.68M 22.35 -$644.76M -$1.20 N/A

Which has higher valuation & earnings, ANL or NUVB?

Adlai Nortye has higher earnings, but lower revenue than Nuvation Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 81.60 -$35.53M N/A N/A Nuvation Bio $62.90M 26.43 -$204.63M -$0.43 N/A

Adlai Nortye (ANL) Competitors

$10.20 -0.27 (-2.58%)

Closing price 06/11/2026 04:00 PM Eastern

Extended Trading

$10.38 +0.19 (+1.81%)

As of 06/11/2026 04:10 PM Eastern

Compare

ANL vs. ZYME, AAPG, NBTX, RXRX, and NUVB

Should you buy Adlai Nortye stock or one of its competitors? MarketBeat compares Adlai Nortye with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adlai Nortye include Zymeworks (ZYME), Ascentage Pharma Group International (AAPG), Nanobiotix (NBTX), Recursion Pharmaceuticals (RXRX), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.

How does Adlai Nortye compare to Zymeworks?

Adlai Nortye (NASDAQ:ANL) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Adlai Nortye has higher earnings, but lower revenue than Zymeworks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	81.60	-$35.53M	N/A	N/A
Zymeworks	$105.96M	15.83	-$81.13M	-$1.37	N/A

Adlai Nortye presently has a consensus target price of $24.25, indicating a potential upside of 137.75%. Zymeworks has a consensus target price of $36.67, indicating a potential upside of 59.63%. Given Adlai Nortye's higher probable upside, equities analysts clearly believe Adlai Nortye is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Adlai Nortye has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

In the previous week, Adlai Nortye and Adlai Nortye both had 1 articles in the media. Zymeworks' average media sentiment score of 1.87 beat Adlai Nortye's score of 0.93 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Positive
Zymeworks	Very Positive

Adlai Nortye has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Adlai Nortye's return on equity of 0.00% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Zymeworks	-126.92%	-37.97%	-25.31%

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zymeworks beats Adlai Nortye on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Ascentage Pharma Group International has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Ascentage Pharma Group International and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.93 beat Ascentage Pharma Group International's score of 0.62 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Positive
Adlai Nortye	Positive

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 171.35%. Adlai Nortye has a consensus price target of $24.25, indicating a potential upside of 137.75%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Adlai Nortye	N/A	N/A	N/A

Adlai Nortye has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.45	-$177.71M	N/A	N/A
Adlai Nortye	$5M	81.60	-$35.53M	N/A	N/A

Summary

Ascentage Pharma Group International beats Adlai Nortye on 6 of the 11 factors compared between the two stocks.

How does Adlai Nortye compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Nanobiotix presently has a consensus target price of $37.33, indicating a potential upside of 5.67%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 137.75%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nanobiotix has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	46.49	-$27.11M	N/A	N/A
Adlai Nortye	$5M	81.60	-$35.53M	N/A	N/A

In the previous week, Nanobiotix had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Adlai Nortye. Nanobiotix's average media sentiment score of 0.96 beat Adlai Nortye's score of 0.93 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Overall Sentiment
Nanobiotix	Positive
Adlai Nortye	Positive

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Adlai Nortye	N/A	N/A	N/A

Nanobiotix has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Nanobiotix beats Adlai Nortye on 6 of the 10 factors compared between the two stocks.

How does Adlai Nortye compare to Recursion Pharmaceuticals?

Adlai Nortye (NASDAQ:ANL) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Adlai Nortye has higher earnings, but lower revenue than Recursion Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	81.60	-$35.53M	N/A	N/A
Recursion Pharmaceuticals	$74.68M	22.35	-$644.76M	-$1.20	N/A

Adlai Nortye has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Adlai Nortye. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.93 beat Recursion Pharmaceuticals' score of 0.62 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Overall Sentiment
Adlai Nortye	Positive
Recursion Pharmaceuticals	Positive

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adlai Nortye has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Adlai Nortye's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Adlai Nortye currently has a consensus price target of $24.25, indicating a potential upside of 137.75%. Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 157.14%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Adlai Nortye beats Recursion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Nuvation Bio?

Adlai Nortye (NASDAQ:ANL) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Adlai Nortye has higher earnings, but lower revenue than Nuvation Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	81.60	-$35.53M	N/A	N/A
Nuvation Bio	$62.90M	26.43	-$204.63M	-$0.43	N/A

Adlai Nortye has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 137.75%. Nuvation Bio has a consensus target price of $12.50, suggesting a potential upside of 161.78%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Nuvation Bio had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Nuvation Bio and 1 mentions for Adlai Nortye. Nuvation Bio's average media sentiment score of 1.23 beat Adlai Nortye's score of 0.93 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Positive
Nuvation Bio	Positive

Adlai Nortye has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Adlai Nortye's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Nuvation Bio	-102.06%	-44.10%	-23.80%

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nuvation Bio beats Adlai Nortye on 8 of the 14 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$418.80M	$3.29B	$6.47B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	N/A	19.62	24.18	24.35
Price / Sales	81.60	302.58	506.88	109.68
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	-48.57	8.21	10.50	6.82
Net Income	-$35.53M	$23.89M	$3.56B	$337.41M
7 Day Performance	2.51%	1.11%	0.22%	2.29%
1 Month Performance	-22.43%	-0.74%	0.67%	3.48%
1 Year Performance	537.50%	40.35%	22.17%	27.16%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	2.0517 of 5 stars	$10.20 -2.6%	$24.25 +137.7%	+518.2%	$418.80M	$5M	N/A	127
ZYME Zymeworks	2.652 of 5 stars	$22.85 -1.8%	$36.67 +60.5%	N/A	$1.67B	$105.96M	N/A	460	Positive News Analyst Forecast
AAPG Ascentage Pharma Group International	4.1247 of 5 stars	$17.45 +2.2%	$46.43 +166.0%	-42.5%	$1.63B	$82.10M	N/A	600	Analyst Forecast Short Interest Increase
NBTX Nanobiotix	3.6286 of 5 stars	$33.55 -2.3%	$37.33 +11.3%	+598.9%	$1.63B	$36.87M	N/A	100	Short Interest Decrease Gap Down
RXRX Recursion Pharmaceuticals	3.4525 of 5 stars	$3.04 -5.6%	$8.10 +166.4%	-41.7%	$1.61B	$74.68M	N/A	400	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. ZYME, AAPG, NBTX, RXRX, and NUVB

How does Adlai Nortye compare to Zymeworks?

Summary

How does Adlai Nortye compare to Ascentage Pharma Group International?

Summary

How does Adlai Nortye compare to Nanobiotix?

Summary

How does Adlai Nortye compare to Recursion Pharmaceuticals?

Summary

How does Adlai Nortye compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. ZYME, AAPG, NBTX, RXRX, and NUVB

How does Adlai Nortye compare to Zymeworks?

Which has preferable valuation & earnings, ANL or ZYME?

Do analysts rate ANL or ZYME?

Which has more volatility & risk, ANL or ZYME?

Does the media favor ANL or ZYME?

Is ANL or ZYME more profitable?

Do institutionals & insiders hold more shares of ANL or ZYME?

Summary

How does Adlai Nortye compare to Ascentage Pharma Group International?

Which has more risk and volatility, AAPG or ANL?

Do insiders & institutionals believe in AAPG or ANL?

Does the media prefer AAPG or ANL?

Do analysts rate AAPG or ANL?

Is AAPG or ANL more profitable?

Which has better valuation and earnings, AAPG or ANL?

Summary

How does Adlai Nortye compare to Nanobiotix?

Do analysts rate NBTX or ANL?

Which has preferable earnings & valuation, NBTX or ANL?

Does the media prefer NBTX or ANL?

Is NBTX or ANL more profitable?

Which has more volatility and risk, NBTX or ANL?

Do insiders and institutionals believe in NBTX or ANL?

Summary

How does Adlai Nortye compare to Recursion Pharmaceuticals?

Which has better valuation and earnings, ANL or RXRX?

Which has more risk and volatility, ANL or RXRX?

Does the media favor ANL or RXRX?

Do institutionals & insiders have more ownership in ANL or RXRX?

Is ANL or RXRX more profitable?

Do analysts prefer ANL or RXRX?

Summary

How does Adlai Nortye compare to Nuvation Bio?

Which has higher valuation & earnings, ANL or NUVB?

Which has more risk & volatility, ANL or NUVB?

Do analysts prefer ANL or NUVB?

Does the media favor ANL or NUVB?

Is ANL or NUVB more profitable?

Do institutionals and insiders have more ownership in ANL or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools